Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct:177:113950.
doi: 10.1016/j.addr.2021.113950. Epub 2021 Aug 26.

Targeted drug delivery for maternal and perinatal health: Challenges and opportunities

Anjali Sharma  1 , Nirnath Sah  2 , Sujatha Kannan  3 , Rangaramanujam M Kannan  4
Affiliations
Review

Targeted drug delivery for maternal and perinatal health: Challenges and opportunities

Anjali Sharma et al. Adv Drug Deliv Rev. 2021 Oct.

Abstract

Pre-existing conditions at reproductive age, and complications arising during pregnancy can be detrimental to maternal and fetal health. Current therapies to combat obstetric disorders are limited due to the inherent complexity of pregnancy, and can have harmful effects on developing fetus. Emerging research shows intricate signaling between the cells from mother and fetus at maternal-fetal interface, providing unique opportunities for interventions specifically targeted to the mother, fetus, or placenta. Advancements in nanotechnology, stem-cell biology and gene therapy have resulted in target-specific treatments with promising results in pre-clinical maternal and fetal disorder models. Comprehensive understanding of the effect of physicochemical properties of delivery systems on their uptake, retention and accumulation across placenta will help in the better diagnosis and treatment of perinatal disorders. This review describes the factors leading to obstetric complications along with their effect on pregnancy outcomes, and discusses key targeted therapeutic strategies for addressing conditions related to maternal and fetal health.

Keywords: Maternal and fetal nanomedicine; Nanoparticles; Obstetric complications; Perinatal health; Targeted drug delivery.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Under license agreements involving Ashvattha Therapeutics Inc and the Johns Hopkins University, RMK, SK, and the University are entitled to royalty distributions and share ownership related to the dendrimer platform discussed in parts of this manuscript. RMK (co-founder) and SK (co-founder) hold equity in Ashvattha Therapeutics and serve on its Board of Directors. This arrangement is managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.].

Figures

Figure 1.
Figure 1.
Schematic illustration demonstrating benefits of targeted drug delivery and nanomedicines in maternal and perinatal health. Nanotechnology mediated controlled drug and gene delivery specifically targeted to mother, placenta, and fetus may provide novel avenues for treating obstetric complications without harming mother and the fetus.
Figure 2.
Figure 2.
Schematic illustration of the implications of maternal insult on pregnancy outcomes. The figure summarizes the maternal conditions, both pre-existing and developed during pregnancy, along with their effects on maternal and perinatal health. The red arrows indicate the temporal evolution of different disease phenotypes in the fetus (left), and the mother (right).
Figure 3.
Figure 3.
Illustration of the role of placenta and the maternal-fetal interface. The placenta represents the connection between the mother and the fetus, and constitutes syncytiotrophoblast, cytotrophoblast, embryonic connective tissue, and endothelial cells of fetal blood vessels.
Figure 4.
Figure 4.
Illustration of molecular transport through placenta. Figure represents various mechanisms of placental molecular transport via active and passive routes at the maternal-fetal interface.
Figure 5.
Figure 5.
Toxic effects of NPs exposure during pregnancy. NPs may exert toxic effects on maternal health, placenta and fetal development and detailed toxicological studied of nanomedicines will be of utmost importance to make use of the modern nanotechnology for safe treatment of obstetric complications.
See this image and copyright information in PMC

References

    1. Rickelt S, Hynes RO, Antibodies and methods for immunohistochemistry of extracellular matrix proteins, Matrix Biol, 71–72 (2018) 10–27. - PubMed
    1. https://www.theworldcounts.com/populations/world/births.
    1. Sachdeva P, Patel BG, Patel BK, Drug use in pregnancy; a point to ponder!, Indian J Pharm Sci, 71 (2009) 1–7. - PMC - PubMed
    1. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, National S Birth Defects Prevention, Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008, American journal of obstetrics and gynecology, 205 (2011) 51.e51–51.e518. - PMC - PubMed
    1. Fisk NM, McKee M, Atun R, Relative and absolute addressability of global disease burden in maternal and perinatal health by investment in R&D, Tropical medicine & international health : TM & IH, 16 (2011) 662–668. - PubMed

Publication types

LinkOut - more resources